Journal of Neuroimmunology
Volume 225, Issue 1 , Pages 43-51 , 25 August 2010

Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity

  • Bin Xing

      Affiliations

    • Department of Anatomy & Neurobiology, Rose 800 Street, University of Kentucky, Lexington, KY 40536, USA
    • These authors contributed equally to this work.
    • Tel.: +1 214 645 6243.
    • ,
  • Tao Xin

      Affiliations

    • Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan 250012, PR China
    • These authors contributed equally to this work.
    • ,
  • Lingling Zhao

      Affiliations

    • Xiangya Third Hospital, Central South University, Changsha, Hunan 410013, PR China
    • ,
  • Randy L. Hunter

      Affiliations

    • Department of Anatomy & Neurobiology, Rose 800 Street, University of Kentucky, Lexington, KY 40536, USA
    • ,
  • Yan Chen

      Affiliations

    • Department of Anatomy & Neurobiology, Rose 800 Street, University of Kentucky, Lexington, KY 40536, USA
    • ,
  • Guoying Bing

      Affiliations

    • Department of Anatomy & Neurobiology, Rose 800 Street, University of Kentucky, Lexington, KY 40536, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 859 323 9708; fax: +1 859 257 3625.

Received 8 December 2009 ,Revised 18 April 2010 ,Accepted 19 April 2010.

References 

  1. Aoi M, Date I, Tomita S, Ohmoto T. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system. Neurol. Res. 2000;22:832–836
  2. Arimoto T, Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 2003;12:35–45
  3. Barthwal MK, Srivastava N, Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep. 2001;6:297–302
  4. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 1998;44:S110–S114
  5. Becq H, Bosler O, Geffard M, Enjalbert A, Herman JP. Anatomical and functional reconstruction of the nigrostriatal system in vitro: selective innervation of the striatum by dopaminergic neurons. J. Neurosci. Res. 1999;58:553–566
  6. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 2001;11:297–305
  7. Carrasco E, Casper D, Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 2007;85:3109–3117
  8. Cheng FC, Ni DR, Wu MC, Kuo JS, Chia LG. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice. Neurosci. Lett. 1998;252:87–90
  9. Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, et al. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE. 2009;4:e5482
  10. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science. 2004;304:1328–1331
  11. Creedon DJ, Tansey MG, Baloh RH, Osborne PA, Lampe PA, Fahrner TJ, et al. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc. Natl Acad. Sci. USA. 1997;94:7018–7023
  12. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005;25:9275–9284
  13. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(Pt 8):1437–1448
  14. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–241
  15. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 2000;74:2213–2216
  16. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994;9:92–97
  17. Ding YM, Jaumotte JD, Signore AP, Zigmond MJ. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J. Neurochem. 2004;89:776–787
  18. Du Y, Li X, Yang D, Zhang X, Chen S, Huang K, et al. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp. Biol. Med. (Maywood). 2008;233:881–890
  19. Elkon H, Melamed E, Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 2004;24:387–400
  20. Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 2003;184:536–548
  21. Floden AM, Combs CK. Microglia repetitively isolated from in vitro mixed glial cultures retain their initial phenotype. J. Neurosci. Meth. 2007;164:218–224
  22. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 2008;28:10825–10834
  23. Franke H, Schelhorn N, Illes P. Dopaminergic neurons develop axonal projections to their target areas in organotypic co-cultures of the ventral mesencephalon and the striatum/prefrontal cortex. Neurochem. Int. 2003;42:431–439
  24. Frebel K, Wiese S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans. 2006;34:1287–1290
  25. Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 2002;22:782–790
  26. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002;81:1285–1297
  27. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 1996;380:252–255
  28. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 2002;133:27–35
  29. Ghribi O, Herman MM, Pramoonjago P, Spaulding NK, Savory J. GDNF regulates the A beta-induced endoplasmic reticulum stress response in rabbit hippocampus by inhibiting the activation of gadd 153 and the JNK and ERK kinases. Neurobiol. Dis. 2004;16:417–427
  30. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003;9:589–595
  31. Glazner GW, Mu X, Springer JE. Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system. J. Comp. Neurol. 1998;391:42–49
  32. Gramsbergen JB, Sandberg M, Moller Dall A, Kornblit B, Zimmer J. Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin. Brain Res. 2002;935:47–58
  33. Granziera C, Thevenet J, Price M, Wiegler K, Magistretti PJ, Badaut J, et al. Thrombin-induced ischemic tolerance is prevented by inhibiting c-jun N-terminal kinase. Brain Res. 2007;1148:217–225
  34. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005;93:105–117
  35. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain. 2002;125:2191–2201
  36. Hashimoto M, Nitta A, Fukumitsu H, Nomoto H, Shen L, Furukawa S. Inflammation-induced GDNF improves locomotor function after spinal cord injury. NeuroReport. 2005;16:99–102
  37. Herrera AJ, Tomas-Camardiel M, Venero JL, Cano J, Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural. Transm. 2005;112:111–119
  38. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 1998;44:S115–S120
  39. Honda S, Nakajima K, Nakamura Y, Imai Y, Kohsaka S. Rat primary cultured microglia express glial cell line-derived neurotrophic factor receptors. Neurosci. Lett. 1999;275:203–206
  40. Hong JS. Role of inflammation in the pathogenesis of Parkinson's disease: models, mechanisms, and therapeutic interventions. Ann. N. Y. Acad. Sci. 2005;1053:151–152
  41. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 1999;162:3749–3752
  42. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience. 1996;72:355–363
  43. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA. 2004;101:665–670
  44. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 2007;100:1375–1386
  45. Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, et al. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J. Neurosci. Res. 2009;87:1913–1921
  46. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 2002;110:49–58
  47. Jana M, Jana A, Liu X, Ghosh S, Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J. Immunol. 2007;179:4142–4152
  48. Jenner, P., 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3, S26-36; discussion S36-28.
  49. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998;44:S72–S84
  50. Kawahara K, Yoshida A, Koga K, Yokoo S, Kuniyasu A, Gotoh T, et al. Marked induction of inducible nitric oxide synthase and tumor necrosis factor-alpha in rat CD40+ microglia by comparison to CD40− microglia. J. Neuroimmunol. 2009;208:70–79
  51. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000;20:6309–6316
  52. King TD, Bijur GN, Jope RS. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 2001;919:106–114
  53. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 2000;16:724–739
  54. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 1999;46:419–424
  55. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000;290:767–773
  56. Kotake Y, Taguchi R, Okuda K, Sekiya Y, Tasaki Y, Hirobe M, et al. Neuroprotective effect of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res. 2005;1033:143–150
  57. Kress GJ, Reynolds IJ. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol. Dis. 2005;20:639–645
  58. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience. 1997;78:61–72
  59. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39:151–170
  60. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci. 2001;21:8447–8455
  61. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 2002;22:2478–2486
  62. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl Acad. Sci. USA. 2003;100:8514–8519
  63. Li FQ, Lu XZ, Liang XB, Zhou HF, Xue B, Liu XY, et al. Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J. Neuroimmunol. 2004;148:24–31
  64. Li FQ, Wang T, Pei Z, Liu B, Hong JS. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. J. Neural. Transm. 2005;112:331–347
  65. Li G, Cui G, Tzeng NS, Wei SJ, Wang T, Block ML, et al. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 2005;19:489–496
  66. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999;5:1403–1409
  67. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130–1132
  68. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol. 2008;209:82–88
  69. Liu B, Wang K, Gao HM, Mandavilli B, Wang JY, Hong JS. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J. Neurochem. 2001;77:182–189
  70. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 2003;305:212–218
  71. Malagelada C, Jin ZH, Greene LA. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 2008;28:14363–14371
  72. Maswood N, Grondin R, Zhang Z, Stanford JA, Surgener SP, Gash DM, et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol. Aging. 2002;23:881–889
  73. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988;24:574–576
  74. McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv. Neurol. 2001;86:83–89
  75. Nagatsu T, Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell. Mol. Neurobiol. 2006;26:781–802
  76. Nakanishi H, Tamura A, Kawai K, Yamamoto K. Electrophysiological studies of rat substantia nigra neurons in an in vitro slice preparation after middle cerebral artery occlusion. Neuroscience. 1997;77:1021–1028
  77. Nguyen VT, Walker WS, Benveniste EN. Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-beta. Eur. J. Immunol. 1998;28:2537–2548
  78. Onyango IG, Tuttle JB, Bennett JP. Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H2O2-induced neuronal death. Neurobiol. Dis. 2005;20:141–154
  79. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005;57:168–175
  80. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005;57:298–302
  81. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088
  82. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood. 2005;106:3114–3122
  83. Reilly CE. Glial cell line-derived neurotrophic factor (GDNF) prevents neurodegeneration in models of Parkinson's disease. J. Neurol. 2001;248:76–78
  84. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 1998;82:129–137
  85. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. NeuroSci. 1999;11:1554–1566
  86. Saavedra A, Baltazar G, Santos P, Carvalho CM, Duarte EP. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron–glia crosstalk. Neurobiol. Dis. 2006;23:533–542
  87. Sarabi A, Hoffer BJ, Olson L, Morales M. GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J. Comp. Neurol. 2001;441:106–117
  88. Sawada H, Ibi M, Kihara T, Urushitani M, Nakanishi M, Akaike A, et al. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J. Neurochem. 2000;74:1175–1184
  89. Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 1995;64:936–939
  90. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003;23:10756–10764
  91. Shibata H, Katsuki H, Nishiwaki M, Kume T, Kaneko S, Akaike A. Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin. J. Neurochem. 2003;86:1201–1212
  92. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 2001;39:167–174
  93. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA. 2003;100:5473–5478
  94. Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 2005;134:109–118
  95. Timmons S, Coakley MF, Moloney AM, C ON. Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 2009;467:30–35
  96. Ugarte SD, Lin E, Klann E, Zigmond MJ, Perez RG. Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J. Neurosci. Res. 2003;73:105–112
  97. van Weering DH, Bos JL. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J. Biol. Chem. 1997;272:249–254
  98. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation. 2006;3:6
  99. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. NeuroSci. 2002;16:2103–2112
  100. Wang T, Liu B, Qin L, Wilson B, Hong JS. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuronal–glial cultures. J. Neuroimmunol. 2004;147:68–72
  101. West MJ. New stereological methods for counting neurons. Neurobiol. Aging. 1993;14:275–285
  102. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002;22:1763–1771
  103. Xing B, Liu M, Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol. 2007;192:89–98
  104. Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neuroinflammation. 2008;5:4
  105. Yasuhara T, Shingo T, Muraoka K, Kobayashi K, Takeuchi A, Yano A, et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J. Neurosurg. 2005;102:80–89
  106. Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknecht C, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 2008;116:47–55
  107. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 2009;[Epub ahead of print]
  108. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533–542
  109. Zhou HF, Liu XY, Niu DB, Li FQ, He QH, Wang XM. Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis. 2005;18:441–449

PII: S0165-5728(10)00170-0

doi: 10.1016/j.jneuroim.2010.04.010

Journal of Neuroimmunology
Volume 225, Issue 1 , Pages 43-51 , 25 August 2010

Article Tools

* Image Usage & Resolution